Abstract
Supplemental Digital Content is available in the text.
Keywords:
COVID-19; cardiovascular diseases; heart; myocarditis; severe acute respiratory syndrome coronavirus 2.
Publication types
-
Letter
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiotensin-Converting Enzyme 2
-
Betacoronavirus / isolation & purification
-
Betacoronavirus / pathogenicity
-
COVID-19
-
Cardiomyopathy, Dilated / genetics
-
Cardiomyopathy, Dilated / pathology
-
Cardiomyopathy, Hypertrophic / genetics
-
Cardiomyopathy, Hypertrophic / pathology
-
Cathepsin L / genetics
-
Cathepsin L / metabolism
-
Coronavirus Infections / complications
-
Coronavirus Infections / pathology*
-
Coronavirus Infections / virology
-
Heart Ventricles / metabolism
-
Humans
-
Myocarditis / diagnosis*
-
Myocarditis / etiology
-
Myocardium / metabolism*
-
Pandemics
-
Peptidyl-Dipeptidase A / chemistry
-
Peptidyl-Dipeptidase A / genetics*
-
Peptidyl-Dipeptidase A / metabolism
-
Pneumonia, Viral / complications
-
Pneumonia, Viral / pathology*
-
Pneumonia, Viral / virology
-
Protease Inhibitors / pharmacology
-
RNA-Seq
-
SARS-CoV-2
-
Serine Endopeptidases / genetics
-
Serine Endopeptidases / metabolism
-
Up-Regulation / drug effects
Substances
-
Protease Inhibitors
-
Peptidyl-Dipeptidase A
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2
-
Serine Endopeptidases
-
TMPRSS2 protein, human
-
CTSL protein, human
-
Cathepsin L